Bayer's NDA219627 Approval and TEVA's ANDA219413 Submission: Shifting Competitive Dynamics
Not specified • Regulatory Approval • Jun 18, 2026
Assessment confidence: 69% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
Executive Thesis
The FDA's approval of Bayer's NDA219627 is a significant regulatory milestone that could enhance Bayer's market position. This approval may shift competitive dynamics, prompting other companies to reassess their strategies in the relevant therapeutic area. Regulatory context from FDA (FDA AP — NDA219627) supports the near-term read. Assessment grounded in 20 ranked evidence items (11 high-relevance).
Strategic Assessment
Portfolio teams should assess the implications of this approval on market share and competitive dynamics. The strongest clinical anchor is Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain in Children (ClinicalTrials.gov), mechanism alignment (io ). In Not specified, 6 regulatory and 4 competitive items passed relevance filtering for Bayer Healthcare Pharmaceuticals.
Competitive Pressure
The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from [Ad hoc announcement pursuant to Art.. This approval may enhance Bayer's position in the market, potentially impacting competitors in the same therapeutic area.
Regulatory Outlook
Regulatory risk is concentrated around FDA AP — NDA219627 (FDA). Entity match (nda219627); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The approval signifies compliance with FDA standards, which is crucial for market access and can influence future regulatory submissions by competitors.
Key Risks
- Elevated high regulatory exposure for Bayer Healthcare Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.
Key Opportunities
- The approval may lead to increased market share for Bayer, affecting revenue projections and competitive positioning against peers in the same therapeutic area.
- Portfolio teams should assess the implications of this approval on market share and competitive dynamics.
What Would Change This Assessment
- This becomes more urgent if Monitor for further details on the drug's indication and market launch plans.
- Timeline shift beyond near term would change urgency.
- A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.
Supporting Evidence
FDA AP — NDA219627
FDAhigh relevance
Entity match (nda219627); Regulatory pathway relevance (nda)
FDA document
View sourceClinical trials for medicines: modifying a clinical trial approval
MHRAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View sourceFDA AP — CHILDREN'S CLARITIN (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain in Children
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View sourceChemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceRetrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceTesting the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006-2025).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceFirst-in-human evaluation of [(18)F]-AlF-NOTA-neurotensin for NTSR1-targeted imaging of prostate cancer: a head-to-head comparison with [(68)Ga]Ga-PSMA-617.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceGut microbial markers of immunotherapy response in melanoma: a cross-cohort analysis including the first Russian dataset.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceAn orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceVariation in gestational outcomes among PCOS phenotypes in natural and art-conceived pregnancies.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Related Signals
- Bayer Healthcare's NDA219627 Receives Approval from FDA
Regulatory Approval
- Bayer's NDA219627 Receives Approval from FDA
Regulatory Approval
- TEVA Pharmaceuticals submits ANDA219413 for FDA review
Regulatory Approval
Related Regulatory Precedents
FDA
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
SourceFDA
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
SourceFDA
Withdrawn | Cancer Accelerated Approvals
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been subsequently withdrawn, and are therefore, no longer FDA-approved.
SourceMHRA
Clinical trials for medicines: modifying a clinical trial approval
Guidance on the various types of modifications that can be made to a clinical trial approval.
SourceFDA
Ongoing | Cancer Accelerated Approvals
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
SourceFDA
FDA AP — VYEPTI (SUPPL)
Application BLA761119. Sponsor: Lundbeck Seattle BioPharmaceuticals, Inc.. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: EPTINEZUMAB-JJMR.
SourceFDA
FDA AP — CHILDREN'S CLARITIN (SUPPL)
Application NDA021891. Sponsor: BAYER HEALTHCARE LLC. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: LORATADINE.
SourceFDA
FDA AP — NDA219627
Application NDA219627. Sponsor: BAYER HEALTHCARE PHARMS. Submission status: AP. Submission type: ORIG. Review priority: STANDARD.
Source